Elevated Capital Advisors’s GSK GSK Stock Holding History

Elevated Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78K	Hold	34	–	–	﹤0.01%	681
2026 Q1	$1.88K	Hold	34	–	–	﹤0.01%	668
2025 Q4	$1.67K	Buy	+34	New	+$1.59K	﹤0.01%	647
2023 Q3	–	Sell	-37,097	Closed	-$1.32M	–	173
2023 Q2	$1.32M	Buy	37,097 +635	+2%	+$22.8K	0.44%	82
2023 Q1	$1.3M	Sell	36,462 -295	-0.8%	-$10.3K	0.46%	80
2022 Q4	$1.29M	Buy	36,757 +2,252	+7%	+$75K	0.49%	72
2022 Q3	$1.01M	Buy	+34,505	New	+$1.31M	0.4%	89
2022 Q1	$1.01M	Buy	+18,638	New	+$1.01M	0.34%	99
2021 Q3	$765K	Buy	+16,014	New	+$804K	0.26%	111
2021 Q1	$634K	Buy	13,459 +697	+5%	+$31.6K	0.25%	116
2020 Q4	$587K	Sell	12,762 -780	-6%	-$35.8K	0.25%	115
2020 Q3	$657K	Sell	13,542 -504	-4%	-$25.3K	0.31%	107
2020 Q2	$701K	Buy	+14,046	New	+$721K	0.33%	107
2019 Q4	$419K	Buy	+7,133	New	+$397K	0.47%	62
2019 Q1	$824K	Buy	+16,552	New	+$827K	0.54%	60

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Elevated Capital Advisors's GSK Position: Q2 2026 in Review

Elevated Capital Advisors held its GSK (GSK) position steady in Q2 2026 at 34 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Elevated Capital Advisors first reported a position in GSK in Q1 2019 and has held it in 15 quarters since. The position peaked at $1.32M in Q2 2023. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Elevated Capital Advisors held 34 shares of GSK worth $1.78K as of Q2 2026.
Elevated Capital Advisors left its GSK share count unchanged in Q2 2026.
GSK made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #681 holding.
Elevated Capital Advisors first reported a position in GSK in Q1 2019 and has held it in 15 quarters since.
Elevated Capital Advisors's GSK position peaked at $1.32M in Q2 2023.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.